Catalent has executed a definitive binding agreement to acquire Metrics Contract Services, a specialized CDMO subsidiary, from Australia-based Mayne Pharma Group. Concurrently with the main transaction, the parties established a five-year commercial supply agreement alongside a transition service agreement (TSA), ensuring a seamless operational integration and absolute supply continuity for the divesting parent’s retained product portfolio. This transaction represents a highly value-accretive platform investment purposefully designed to expand integrated global oral solid formulation capabilities. The core industrial logic centers on securing immediate, fit-for-scale capacity in the specialized potent handling space. With biopharma R&D pipelines increasingly pivoting towards complex oncology and rare disease programs, securing advanced potent compound manufacturing capabilities efficiently mitigates supply chain shortfalls. Furthermore, the seamless integration of a state-of-the-art facility significantly accelerates an ongoing capacity expansion blitz, allowing the acquirer to rapidly meet escalating client demand without the extensive lead times typically associated with greenfield development. This operation sends a definitive signal of continued sector consolidation within the high-value CDMO landscape. It highlights a robust appetite among tier-one industry players to deploy dry powder for premium niche capabilities, particularly within the high-barrier-to-entry potent drug handling segment. This move establishes a rigorous benchmark for asset valuations within the oral solid dose niche, reaffirming that state-of-the-art infrastructure catering to high-growth therapeutic areas continues to command exceptional strategic interest.

METRICS CONTRACT SERVICES, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.